Price Size
$280 100ul
$350 200ul

Same day delivery

Contact distributor
  • Product Name
    Phospho-JNK1/2/3 (Thr183+Tyr185) Antibody
  • Catalog No.
    AF3318
  • Source
    Rabbit
  • Application
    WB,IHC,IF/ICC,ELISA
  • Reactivity:
    Human, Mouse, Rat
  • Prediction:
    Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
  • UniProt
  • Mol.Wt.
    46,54kDa
  • Concentration
    1mg/ml
  • Browse similar products>>

Product Information

Alternative Names:Expand▼

C Jun kinase 2; c Jun N terminal kinase 1; c Jun N terminal kinase 2; c Jun N terminal kinase 3; c-Jun N-terminal kinase 1; JNK 46; JNK 55; JNK; JNK-46; JNK1; JNK1A2; JNK2; JNK21B1/2; JNK2A; JNK2ALPHA; JNK2B; JNK2BETA; JNK3 alpha protein kinase; JNK3; JNK3A; Jun kinase; JUN N terminal kinase; MAP kinase 10; MAP kinase 8; MAP kinase 9; MAP kinase p49 3F12; MAPK 10; MAPK 8; MAPK 9; MAPK10; mapk8; MAPK9; Mitogen activated protein kinase 10; Mitogen activated protein kinase 8; Mitogen activated protein kinase 8 isoform JNK1 alpha1; Mitogen activated protein kinase 8 isoform JNK1 beta2; Mitogen activated protein kinase 9; Mitogen-activated protein kinase 8; MK08_HUMAN; p493F12; p54a; p54aSAPK; p54bSAPK; PRKM10; PRKM8; PRKM9; SAPK; SAPK(beta); SAPK1; SAPK1a; SAPK1b; SAPK1c; Stress activated protein kinase 1; Stress activated protein kinase 1a; Stress activated protein kinase 1b; Stress activated protein kinase 1c; Stress activated protein kinase beta; Stress activated protein kinase JNK1; Stress activated protein kinase JNK2; Stress activated protein kinase JNK3; Stress-activated protein kinase 1c; Stress-activated protein kinase JNK1; c Jun kinase 2; C Jun N terminal kinase 2; c-Jun N-terminal kinase 2; JNK 55; JNK-55; JNK2 alpha; JNK2; JNK2 beta; JNK2A; JNK2alpha; JNK2B; JNK2BETA; Jun kinase; MAP kinase 9; MAPK 9; Mapk9; Mitogen activated protein kinase 9; Mitogen-activated protein kinase 9; MK09_HUMAN; P54a; p54aSAPK; PRKM9; Protein kinase, mitogen-activated, 9; SAPK alpha; SAPK; SAPK1a; Stress activated protein kinase 1a; Stress-activated protein kinase JNK2; c Jun kinase 3; c-Jun N-terminal kinase 3; cJun N terminal kinase 3; FLJ12099; FLJ33785; JNK3 alpha protein kinase; JNK3; JNK3A; MAP kinase 10; MAP kinase; MAP kinase p49 3F12; MAPK 10; Mapk10; MGC50974; mitogen activated protein kinase 10; Mitogen-activated protein kinase 10; MK10_HUMAN; p493F12; p54bSAPK; PRKM10; protein kinase mitogen activated 10; SAPK1b; Stress activated protein kinase 1b; stress activated protein kinase beta; Stress activated protein kinase JNK3; Stress-activated protein kinase JNK3;

Applications:

WB 1:500-1:2000, IHC 1:100-1:500, IF 1:100-1:500, ELISA(peptide) 1:20000-1:40000

Reactivity:

Human, Mouse, Rat

Predicted Reactivity:

Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)

Source:

Rabbit

Clonality:

Polyclonal

Purification:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

Specificity:

Phospho-JNK1/2/3 (Thr183+Tyr185) Antibody detects endogenous levels of JNK1/2/3 only when phosphorylated at Threonine 183+Tyrosine 185.

Format:

Liquid

Concentration:

1mg/ml

Storage Condition and Buffer:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.

Immunogen Information

Immunogen:

A synthesized peptide derived from human JNK1/2/3 around the phosphorylation site of Thr183+Tyr185.

Uniprot:



>>Visit The Human Protein Atlas

Gene id:

Molecular Weight:

Observed Mol.Wt.: 46,54kDa.
Predicted Mol.Wt.: 49kDa.

Subcellular Location:

Cytoplasm. Nucleus.

Description:

JNK3 a protein kinase of the MAPK family that is potently activated by a variety of environmental stress and pro-inflammatory cytokines. Brain-selective JNK isoform.

Sequence:
        10         20         30         40         50
MSRSKRDNNF YSVEIGDSTF TVLKRYQNLK PIGSGAQGIV CAAYDAILER
60 70 80 90 100
NVAIKKLSRP FQNQTHAKRA YRELVLMKCV NHKNIIGLLN VFTPQKSLEE
110 120 130 140 150
FQDVYIVMEL MDANLCQVIQ MELDHERMSY LLYQMLCGIK HLHSAGIIHR
160 170 180 190 200
DLKPSNIVVK SDCTLKILDF GLARTAGTSF MMTPYVVTRY YRAPEVILGM
210 220 230 240 250
GYKENVDLWS VGCIMGEMVC HKILFPGRDY IDQWNKVIEQ LGTPCPEFMK
260 270 280 290 300
KLQPTVRTYV ENRPKYAGYS FEKLFPDVLF PADSEHNKLK ASQARDLLSK
310 320 330 340 350
MLVIDASKRI SVDEALQHPY INVWYDPSEA EAPPPKIPDK QLDEREHTIE
360 370 380 390 400
EWKELIYKEV MDLEERTKNG VIRGQPSPLG AAVINGSQHP SSSSSVNDVS
410 420
SMSTDPTLAS DTDSSLEAAA GPLGCCR

Background

Function:

Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock (PubMed:22441692). Phosphorylates the heat shock transcription factor HSF1, suppressing HSF1-induced transcriptional activity (PubMed:10747973).

Post-translational Modifications:

Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4, which activates the enzyme (PubMed:11062067). Phosphorylated by TAOK2 (PubMed:17158878). May be phosphorylated at Thr-183 and Tyr-185 by MAP3K1/MEKK1 (PubMed:17761173).

Subcellular Location:

Nucleus;

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionGraphics by Christian Stolte

Subunit Structure:

Binds to at least four scaffolding proteins, MAPK8IP1/JIP-1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4 (PubMed:15693750). These proteins also bind other components of the JNK signaling pathway. Interacts with TP53 and WWOX (PubMed:12514174). Interacts with JAMP (By similarity). Forms a complex with MAPK8IP1 and ARHGEF28 (By similarity). Interacts with HSF1 (via D domain and preferentially with hyperphosphorylated form); this interaction occurs under both normal growth conditions and immediately upon heat shock (PubMed:10747973). Interacts (phosphorylated form) with NFE2; the interaction phosphorylates NFE2 in undifferentiated cells (By similarity). Interacts with NFATC4 (PubMed:17875713). Interacts with MECOM; regulates JNK signaling (PubMed:10856240). Interacts with PIN1; this interaction mediates MAPK8 conformational changes leading to the binding of MAPK8 to its substrates (PubMed:21660049). Interacts with GRIPAP1 (PubMed:17761173).

Similarity:

The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases.Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily.

Research Fields

Research Fields:

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.(View pathway)
· Cellular Processes > Cellular community - eukaryotes > Tight junction.(View pathway)
· Cellular Processes > Cell growth and death > Apoptosis.(View pathway)
· Cellular Processes > Transport and catabolism > Autophagy - animal.(View pathway)
· Cellular Processes > Cell growth and death > Apoptosis - multiple species.(View pathway)
· Cellular Processes > Cell growth and death > Necroptosis.(View pathway)
· Environmental Information Processing > Signal transduction > TNF signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > MAPK signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > ErbB signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Wnt signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > FoxO signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Ras signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > cAMP signaling pathway.(View pathway)
· Genetic Information Processing > Folding, sorting and degradation > Protein processing in endoplasmic reticulum.(View pathway)
· Human Diseases > Cancers: Specific types > Pancreatic cancer.(View pathway)
· Human Diseases > Cancers: Overview > Pathways in cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Colorectal cancer.(View pathway)
· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.
· Human Diseases > Infectious diseases: Bacterial > Pertussis.
· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.
· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.
· Human Diseases > Cancers: Overview > Choline metabolism in cancer.(View pathway)
· Human Diseases > Infectious diseases: Bacterial > Shigellosis.
· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.
· Human Diseases > Infectious diseases: Viral > Hepatitis C.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).
· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.
· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).
· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.
· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.
· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.(View pathway)
· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.(View pathway)
· Organismal Systems > Immune system > Toll-like receptor signaling pathway.(View pathway)
· Organismal Systems > Immune system > IL-17 signaling pathway.(View pathway)
· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.(View pathway)
· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.
· Organismal Systems > Endocrine system > Relaxin signaling pathway.
· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.
· Organismal Systems > Endocrine system > Insulin signaling pathway.(View pathway)
· Organismal Systems > Immune system > Th17 cell differentiation.(View pathway)
· Organismal Systems > Endocrine system > Prolactin signaling pathway.(View pathway)
· Organismal Systems > Nervous system > Neurotrophin signaling pathway.(View pathway)
· Organismal Systems > Nervous system > Dopaminergic synapse.
· Organismal Systems > Development > Osteoclast differentiation.(View pathway)
· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels.(View pathway)
· Organismal Systems > Immune system > NOD-like receptor signaling pathway.(View pathway)
· Organismal Systems > Nervous system > Retrograde endocannabinoid signaling.(View pathway)

Western blot analysis of Phospho-JNK1/2/3 (Thr183+Tyr185) using various lysates Lanes 1 - 2: Merged signal (red and green). Green - AF3318 observed at 46,54 kDa. Red - loading control, T0023, observed at 55 kDa. Blots were developed with Goat Anti-Rabbit IgG(H+L) FITC–conjugated (S0008) and Goat Anti-Mouse IgG(H+L) Alexa Fluor 594–conjugated (S0005) secondary antibodies
Western blot analysis of extracts from mouse brain/rat heart, using Phospho-JNK1/2/3 (Thr183+Tyr185) Antibody. -/+ means absence or presence of N peptide(non-phospho peptide) and P peptide(phospho peptide)
AF3318 at 1/200 staining Rat ganstric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Rat ganstric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Rat kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Rat lung tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Rat lung tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse spleen tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse spleen tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse spleen tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse testis tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Mouse testis tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Human bladder cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Human bladder cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Human liver cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Human heart tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF3318 at 1/200 staining Human heart tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-JNK1/2/3 (Thr183+Tyr185) Antibody for IHC in human brain tissue.
AF3318 staining 293 by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody.
AF3318 staining HeLa  cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Red), diluted at 1/600, was used as secondary antibody.
ELISA analysis of AF3318 showing specificity to Phospho-JNK1/2/3 (Thr183+Tyr185) peptide. Peptides concentration: 1ug/ml.
P-peptide: phospho-peptide; N-peptide: non-phospho-peptide.

Reference Citations:

1). Zhang J et al. S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia. Br J Haematol 2019 Mar 27 (PubMed: 30916375) [IF=5.206]

2). Fan H et al. The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activation of the NF-κB and MAPK/p38 pathways. Phytomedicine 2019 Feb 18;58:152864 (PubMed: 30878874) [IF=4.180]

3). Geng J et al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. Biomed Pharmacother 2018 Jan;97:941-947 (PubMed: 29136772)

4). Meng Zhou et al. Administration of CoCl 2 Improves Functional Recovery in a Rat Model of Sciatic Nerve Transection Injury. Int J Med Sci 2018; 15(13):1423-1432

5). Zhang BB et al. Neuroprotective Effects of Dammarane-Type Saponins from Panax notoginseng on Glutamate-Induced Cell Damage in PC12 Cells. Planta Med 2019 Feb 21 (PubMed: 30791058)

6). Wang R et al. PM2.5 upregulates rat mesenteric arteries 5-HT2A receptor via inflammatory-mediated mitogen-activated protein kinases signaling pathway. Environ Toxicol 2019 Jun 14 (PubMed: 31199065)

7). Zhang X et al. Neuroprotective Effect of Modified Xijiao Dihuang Decoction against Oxygen-Glucose Deprivation and Reoxygenation-Induced Injury in PC12 Cells: Involvement of TLR4-MyD88/NF-κB Signaling Pathway. Evid Based Complement Alternat Med 2017;2017:3848595 (PubMed: 29234386)

8). Tang Q et al. Ferroptosis is newly characterized form of neuronal cell death in response to arsenite exposure. Neurotoxicology 2018 Jul;67:27-36 (PubMed: 29678591)

9). An S et al. Administration of CoCl2 Improves Functional Recovery in a Rat Model of Sciatic Nerve Transection Injury. Int J Med Sci 2018 Sep 7;15(13):1423-1432 (PubMed: 30443161)

10). Jin X et al. Tiliroside, the major component of Agrimonia pilosa Ledeb ethanol extract, inhibits MAPK/JNK/p38-mediated inflammation in lipopolysaccharide-activated RAW 264.7 macrophages. Exp Ther Med 2016 Jul;12(1):499-505 (PubMed: 27347085)

Application: WB    Species:mouse;    Sample:Not available

Figure 7. Effect of tiliroside on the phosphorylation of mitogen‑activated protein kinase‑ERK/JNK/p38 proteins. (A) RAW 264.7 cells were treated with LPS 1 µg/ml with or without tiliroside (12.5, 25, 50, and 100 µM) for 45 min and the expression of p‑ERK1/2, p‑JNK and p‑p38 was assessed by western blot analysis. Detection of β‑actin was conducted to confirm the equal loading of proteins. Densitometric analysis of p‑ERK1/2 (B) p‑JNK (C) and p‑p38 (D) expression represent the mean±standard deviation of three separate experiments. Data were normalized with respect to β‑actin levels. **P


11). Zhang Q et al. Anti-inflammatory action of ambuic acid, a natural product isolated from the solid culture of Pestalotiopsis neglecta, through blocking ERK/JNK mitogen-activated protein kinase signaling pathway. Exp Ther Med 2018 Aug;16(2):1538-1546 (PubMed: 30116402)

12). Yang Y et al. Black Sesame Seeds Ethanol Extract Ameliorates Hepatic Lipid Accumulation, Oxidative Stress and Insulin Resistance in Fructose-induced Nonalcoholic Fatty Liver Disease. J Agric Food Chem 2018 Sep 24 (PubMed: 30244573)

13). Li S et al. Effect of CAPE-pNO2 against type 2 diabetes mellitus via the AMPK/GLUT4/ GSK3β/PPARα pathway in HFD/STZ-induced diabetic mice. Eur J Pharmacol 2019 Mar 15;853:1-10 (PubMed: 30885574)

14). Yang B et al. Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop. J Exp Clin Cancer Res 2019 Jul 1;38(1):283 (PubMed: 31262330)

15). Geng H et al. Cigarette smoke extract-induced proliferation of normal human urothelial cells via the MAPK/AP-1 pathway. Oncol Lett 2017 Jan;13(1):469-475 (PubMed: 28123584)

Application: WB    Species:human;    Sample:SV-HUC-1 cells

Figure 4. (A) Fold change in cell viability of SV-HUC-1 cells treated with 0, 0.10 and 0.25% CSE for 7 days in combination with 5 µM U0126, 5 µM SB203580 or 2 µM SP600125. Data are representative of three independent experiments and are expressed as the mean ± standard deviation. * P


16). Li H et al. Dysifragilone A inhibits LPS‑induced RAW264.7 macrophage activation by blocking the p38 MAPK signaling pathway. Mol Med Rep 2018 Jan;17(1):674-682 (PubMed: 29115475)

17). Li Zhao et al. MAPK/AP‑1 pathway regulates benzidine‑induced cell proliferation through the control of cell cycle in human normal bladder epithelial cells. ONCOL LETT 2018;16(4):4628-4634

18). Liu Y et al. (3R, 7R)-7-Acetoxyl-9-Oxo-de-O-Methyllasiodiplodin, a Secondary Metabolite of Penicillium Sp., Inhibits LPS-Mediated Inflammation in RAW 264.7 Macrophages through Blocking ERK/MAPKs and NF-κB Signaling Pathways. Inflammation 2019 Apr 23 (PubMed: 31011928)

19). Peng J et al. MiR-377 promotes white adipose tissue inflammation and decreases insulin sensitivity in obesity via suppression of sirtuin-1 (SIRT1). Oncotarget 2017 Jul 31;8(41):70550-70563 (PubMed: 29050301)

Application: WB    Species:mouse;    Sample:Not available

Figure 4: MiR-377 promotes inflammation and insulin-resistance in mature 3T3-L1 cells. After transfection with 100 nM miR-377 mimics or inhibitor for 24 h, differentiated 3T3-L1 adipocytes were treated with 10 ng/ml TNFα for 24 h and then stimulated with 100 nM insulin for 15 min. Cells were then harvested for real-time PCR and immunoblotting analyses. (A) The effect of miR-377 overexpression on inflammation-related gene expression. *P < 0.05, **P < 0.01 vs. NC 0.1% BSA; ##P < 0.01 vs. NC 10 ng/ml TNFα; ns, not signifcant (n = 3). (B) The effect of miR-377 inhibition on inflammation-related gene expression under conditions of TNFα-induced insulin-resistance. ##P < 0.01 vs. NC 10 ng/ml TNFα(n = 3). (C) The effect of miR-377 overexpression on JNK phosphorylation under conditions of TNFα-induced insulin-resistance. *P < 0.05 vs. NC without insulin; #P < 0.05 vs. NC with insulin (n = 3). (D and E) The effect of miR-377 overexpression on AKT and ERK phosphorylation. *P < 0.05 vs. NC with 0.1% BSA and insulin; #P < 0.05 vs. NC with 10 ng/ml TNFα and insulin (n = 3). (F) The effect of miR-377 inhibition on JNK phosphorylation under conditions of TNFα-induced insulin-resistance. *P < 0.05 vs. NC without insulin; #P < 0.05 vs. NC with insulin (n = 3). (G and H) The effect of miR-377 inhibition on AKT and ERK phosphorylation. *P < 0.05 vs. NC with 0.1% BSA and insulin; #P < 0.05 vs. NC with 10 ng/ml TNFα and insulin (n = 3).


20). Ji M et al. The p75 neurotrophin receptor might mediate sepsis-induced synaptic and cognitive impairments. Behav Brain Res 2018 Jul 16;347:339-349 (PubMed: 29604364)

21). Zhao L et al. MAPK/AP-1 pathway regulates benzidine-induced cell proliferation through the control of cell cycle in human normal bladder epithelial cells. Oncol Lett 2018 Oct;16(4):4628-4634 (PubMed: 30197677)

22). Zhang T et al. Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis. Oncol Rep 2019 Mar 7 (PubMed: 30864736)

23). Jin X et al. 11-O-acetylcyathatriol inhibits MAPK/p38-mediated inflammation in LPS-activated RAW 264.7 macrophages and has a protective effect on ethanol-induced gastric injury. Mol Med Rep 2016 Jul;14(1):874-80 (PubMed: 27222252)

Application: WB    Species:mouse;    Sample:Not available

Figure 3. Effects of 11‑O‑acetylcyathatriol on the protein expression levels of iNOS and COX‑2. The RAW 264.7 cells were treated by 1 µg/ml of LPS with indicated concentrations of 11-O‑acetylcyathatriol (12.5, 25, 50 and 100 µM) for 24 h, and the expression levels of (A) iNOS and COX‑2 were detected using western blot analysis. (B) Effects of 11‑O-acetylcyathatriol on the phosphorylation of ERK1/2, JNK and p38 proteins. RAW 264.7 cells were treated with 1 µg/ml LPS with 11‑O‑acetylcyathatriol (12.5, 25, 50 and 100 µM) for 30 min, and the protein expression levels of p‑ERK1/2, p‑JNK and p‑p38 were detected using western blot analysis. (C) Effects of 11‑O-acetylcyathatriol on the protein degradation of IκB-α. RAW 264.7 cells were treated with 1 µg/ml of LPS with 11-O‑acetylcyathatriol (12.5, 25, 50 and 100 µM) for 10 min, and the protein expression of IκB-α was detected using western blot analysis. iNOS, inducible nitric oxide synthase; COX‑2, cyclooxygenase‑2; LPS, lipopolysaccharide; ERK, extracellular signal‑regulated kinase; JNK, c‑Jun N‑terminal kinase; IκB-α, inhibitor of nuclear factor-κB-α; p‑, phosphorylated.


No comment
Total 0 records, divided into1 pages. First Prev Next Last

Submit Review

Support JPG, GIF, PNG format only
captcha
Catalog Number :

AF3318-BP

Price/Size :

$200/1mg.
Tips: For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Function :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

Format and storage :

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions :

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Xenopus
100%
Chicken
100%
Rabbit
100%
Pig
100%
Dog
100%
Bovine
100%
Sheep
100%
Horse
100%
Zebrafish
79%
High similarity Medium similarity Low similarity No similarity
P45983/P45984/P53779 as Substrate
Site PTM Type Enzyme
S2 Phosphorylation
K30 Ubiquitination
K56 Ubiquitination
K68 Ubiquitination
C116 S-Nitrosylation
S129 Phosphorylation Q05655 (PRKCD)
S144 Phosphorylation
K153 Ubiquitination
S155 Phosphorylation
K160 Ubiquitination
K166 Ubiquitination
T178 Phosphorylation
S179 Phosphorylation
T183 Phosphorylation P45985 (MAP2K4) , O14733 (MAP2K7) , Q99683 (MAP3K5) , O95382 (MAP3K6)
Y185 Phosphorylation P45985 (MAP2K4) , P07949 (RET) , Q99683 (MAP3K5) , O14733 (MAP2K7) , O95382 (MAP3K6)
T188 Phosphorylation
T243 Phosphorylation
K250 Ubiquitination
K251 Ubiquitination
T255 Phosphorylation
T258 Phosphorylation
Y259 Phosphorylation
K265 Ubiquitination
K273 Ubiquitination
K288 Ubiquitination
S292 Phosphorylation
K300 Ubiquitination
S307 Phosphorylation
K308 Acetylation
K308 Ubiquitination
K336 Ubiquitination
K353 Ubiquitination
Y357 Phosphorylation
T367 Phosphorylation
S377 Phosphorylation
Site PTM Type Enzyme
K56 Ubiquitination
K68 Ubiquitination
S144 Phosphorylation
K153 Ubiquitination
S155 Phosphorylation
K160 Ubiquitination
C163 S-Nitrosylation
K166 Ubiquitination
T178 Phosphorylation
T183 Phosphorylation O14733 (MAP2K7)
Y185 Phosphorylation P45985 (MAP2K4) , P07949 (RET) , O14733 (MAP2K7)
T188 Phosphorylation
K250 Acetylation
K250 Ubiquitination
K251 Ubiquitination
S292 Phosphorylation
K300 Ubiquitination
S311 Phosphorylation
K353 Ubiquitination
Y357 Phosphorylation
T386 Phosphorylation
T404 Phosphorylation O14733 (MAP2K7) , P68400 (CSNK2A1)
S407 Phosphorylation P68400 (CSNK2A1) , O14733 (MAP2K7)
Site PTM Type Enzyme
K94 Ubiquitination
K106 Ubiquitination
T131 Phosphorylation Q00535 (CDK5)
S182 Phosphorylation
K191 Ubiquitination
S193 Phosphorylation
K198 Ubiquitination
K204 Ubiquitination
T216 Phosphorylation
S217 Phosphorylation
T221 Phosphorylation O14733 (MAP2K7)
Y223 Phosphorylation P45985 (MAP2K4)
T226 Phosphorylation
T281 Phosphorylation
K288 Ubiquitination
K289 Ubiquitination
S330 Phosphorylation
K346 Acetylation
K391 Ubiquitination
P45983/P45984/P53779 as PTM Enzyme
Substrate Site Source
O00418 (EEF2K) S396 HPRD
O43521-2 (BCL2L11) S44 Calculation
O43521-17 (BCL2L11) T56 Calculation
O43521-2 (BCL2L11) S58 Calculation
O43521-1 (BCL2L11) S59 HPRD
O43521-1 (BCL2L11) S69 HPRD, neXtProt, Signor
O43521-1 (BCL2L11) S77 HPRD
O43521-1 (BCL2L11) S104 HPRD, neXtProt
O43521 (BCL2L11) T116 HPRD, neXtProt, Signor
O43521-1 (BCL2L11) S118 HPRD, neXtProt
O43524 (FOXO3) S574 Calculation
O43561-2 (LAT) T155 Calculation
O43561 (LAT) T184 neXtProt, Signor
O95644 (NFATC1) S172 Calculation
P01106 (MYC) T58 neXtProt
P01106 (MYC) S62 Signor
P01106 (MYC) S71 Signor
P01106-2 (MYC) S77 HPRD
P01106-2 (MYC) S86 HPRD
P04150 (NR3C1) S226 Signor
P04637 (TP53) S20 Signor
P04637 (TP53) S37 neXtProt
P04637-1 (TP53) T81 Signor
P05067-4 (APP) T668 Calculation
P05067 (APP) T743 neXtProt, Signor
P05412 (JUN) S63 Calculation
P05412 (JUN) S73 Calculation
P05412 (JUN) T91 Calculation
P05412 (JUN) T93 Calculation
P05787 (KRT8) S74 Signor
P05787 (KRT8) S432 Calculation
P08047 (SP1) T278 Signor
P08047 (SP1) T739 Signor
P10275 (AR) S651 Calculation
P10276 (RARA) T181 Calculation
P10276 (RARA) S445 Calculation
P10276 (RARA) S461 Calculation
P10415-1 (BCL2) T69 Signor
P10415 (BCL2) S70 Signor
P10415 (BCL2) S87 Signor
P10636-8 (MAPT) T181 Calculation
P10636-8 (MAPT) S202 Calculation
P10636-8 (MAPT) T231 Calculation
P10636-8 (MAPT) S396 Calculation
P10636 (MAPT) T498 neXtProt
P10636 (MAPT) S516 neXtProt
P10636 (MAPT) S519 neXtProt
P10636 (MAPT) T522 neXtProt
P10636 (MAPT) T529 neXtProt
P10636 (MAPT) T534 neXtProt
P10636 (MAPT) S713 neXtProt
P10636 (MAPT) S721 neXtProt
P10636 (MAPT) S739 neXtProt
P14618-2 (PKM) T365 Calculation
P15336 (ATF2) T69 Signor
P15336 (ATF2) T71 Signor
P15336 (ATF2) S90 Calculation
P16104 (H2AFX) S140 neXtProt, Signor
P16949 (STMN1) S25 neXtProt
P16949 (STMN1) S38 neXtProt, Signor
P17275 (JUNB) T102 Calculation
P17275 (JUNB) T104 Calculation
P17535 (JUND) S90 neXtProt
P17535 (JUND) S100 Signor
P17535 (JUND) T117 neXtProt
P19419 (ELK1) S383 Signor
P19419 (ELK1) S389 Signor
P19793 (RXRA) S56 neXtProt
P19793 (RXRA) S70 neXtProt
P19793 (RXRA) T82 neXtProt
P19793 (RXRA) S260 Signor
P22736 (NR4A1) S95 Signor
P23443 (RPS6KB1) S434 neXtProt
P29353 (SHC1) S36 neXtProt
P30305-2 (CDC25B) S101 Calculation
P30305-2 (CDC25B) S103 Calculation
P30305 (CDC25B) S115 neXtProt
P30305 (CDC25B) S117 neXtProt
P30307 (CDC25C) S168 Signor
P31946 (YWHAB) S186 Signor
P31947 (SFN) S186 Signor
P35222 (CTNNB1) S33 Calculation
P35222 (CTNNB1) S37 Calculation
P35222 (CTNNB1) T41 Calculation
P35568 (IRS1) S307 Signor
P35568 (IRS1) S312 Signor
P35568 (IRS1) S315 Signor
P35568 (IRS1) S616 Signor
P35568 (IRS1) S636 Signor
P36956-3 (SREBF1) T81 Calculation
P36956-3 (SREBF1) S93 Calculation
P36956 (SREBF1) S117 Calculation
P37231-2 (PPARG) S84 HPRD
P37231 (PPARG) S112 Signor
P38936 (CDKN1A) T57 Calculation
P38936 (CDKN1A) S98 Calculation
P38936 (CDKN1A) S130 Signor
P40763-2 (STAT3) S726 HPRD
P40763 (STAT3) S727 Signor
P41970 (ELK3) S357 HPRD, neXtProt
P41970 (ELK3) S363 neXtProt
P41970 (ELK3) S396 neXtProt
P41970 (ELK3) S401 neXtProt
P42224 (STAT1) S727 neXtProt
P42226 (STAT6) S707 Signor
P49023 (PXN) S178 Calculation
P54259 (ATN1) S739 Signor
P55957 (BID) T59 Calculation
P61978 (HNRNPK) S216 Signor
P61978 (HNRNPK) S353 Signor
P63104-1 (YWHAZ) S184 Signor
P68431 (HIST1H3J) S29 neXtProt
P78352 (DLG4) S295 neXtProt
P84243 (H3F3B) S29 Signor
P98177 (FOXO4) T227 Calculation
P98177 (FOXO4) S230 Calculation
P98177 (FOXO4) T451 Signor
P98177 (FOXO4) T455 Signor
Q00613-1 (HSF1) S363 HPRD, neXtProt, Signor
Q01844 (EWSR1) T79 Calculation
Q05639 (EEF1A2) S205 Calculation
Q05639 (EEF1A2) S358 Calculation
Q06481 (APLP2) T736 Signor
Q07817 (BCL2L1) T47 Calculation
Q07817 (BCL2L1) S62 Signor
Q07817 (BCL2L1) T115 Calculation
Q07820 (MCL1) S64 Calculation
Q07820 (MCL1) S121 Calculation
Q07820 (MCL1) T163 Signor
Q12904 (AIMP1) S140 Signor
Q12904 (AIMP1) T164 neXtProt
Q13043 (STK4) S82 Signor
Q13363 (CTBP1) S422 Signor
Q13950 (RUNX2) S118 Calculation
Q14653 (IRF3) S173 Signor
Q14934 (NFATC4) S213 Calculation
Q14934 (NFATC4) S217 Calculation
Q15672 (TWIST1) S68 Signor
Q16621 (NFE2) S157 Calculation
Q5JR12 (PPM1J) S93 neXtProt, Signor
Q5JR12 (PPM1J) T201 neXtProt
Q5JR12 (PPM1J) T204 neXtProt
Q8N122 (RPTOR) S696 Calculation
Q8N122 (RPTOR) T706 Calculation
Q8N122 (RPTOR) S863 Calculation
Q8WYK2-1 (JDP2) T148 HPRD, neXtProt
Q92934 (BAD) S75 neXtProt
Q92934 (BAD) S91 neXtProt
Q93045 (STMN2) S62 neXtProt
Q93045 (STMN2) S73 neXtProt
Q96EB6 (SIRT1) S27 Signor
Q96EB6 (SIRT1) S47 Signor
Q96EB6 (SIRT1) T530 Signor
Q96J02 (ITCH) S240 neXtProt, Signor
Q96J02 (ITCH) T263 neXtProt, Signor
Q96J02 (ITCH) S273 neXtProt, Signor
Q96LC9-2 (BMF) S74 Calculation
Q96LC9-2 (BMF) S77 HPRD
Q99607 (ELF4) S641 Calculation
Q99640 (PKMYT1) S83 neXtProt
Q9H211 (CDT1) T29 Calculation
Q9H2B2 (SYT4) S135 Calculation
Q9NPI6 (DCP1A) S315 Calculation
Q9NR28 (DIABLO) S6 Calculation
Q9NR28 (DIABLO) S9 Calculation
Q9NRA8 (EIF4ENIF1) S301 Signor
Q9NRA8 (EIF4ENIF1) S374 Signor
Q9NRA8 (EIF4ENIF1) S513 Signor
Q9NRA8 (EIF4ENIF1) S587 Signor
Q9NRA8 (EIF4ENIF1) S693 Signor
Q9NRA8 (EIF4ENIF1) S752 Signor
Q9UPT6-1 (MAPK8IP3) T265 HPRD, neXtProt, Signor
Q9UPT6-1 (MAPK8IP3) T275 HPRD, neXtProt, Signor
Q9UPT6 (MAPK8IP3) T286 HPRD, neXtProt, Signor
Q9UQF2 (MAPK8IP1) S15 HPRD
Q9UQF2 (MAPK8IP1) S29 HPRD
Q9UQF2 (MAPK8IP1) T103 Signor
Q9UQF2 (MAPK8IP1) S197 HPRD
Q9UQF2 (MAPK8IP1) T205 Calculation
Q9UQF2 (MAPK8IP1) T284 HPRD
Q9UQF2 (MAPK8IP1) S341 HPRD
Q9UQF2 (MAPK8IP1) S421 HPRD
Q9Y4H2 (IRS2) T350 neXtProt
Q9Y4H2 (IRS2) S491 neXtProt
Q9Y5Q3 (MAFB) T62 neXtProt
Q9Y6Q9 (NCOA3) T24 Calculation
Q9Y6Q9 (NCOA3) S505 Calculation
Q9Y6Q9 (NCOA3) S543 Calculation
Q9Y6Q9 (NCOA3) S860 Calculation
Q9Y6Q9 (NCOA3) S867 Calculation
Substrate Site Source
O00418 (EEF2K) S396 HPRD
O43521-2 (BCL2L11) T56 phospho.ELM
O43521-1 (BCL2L11) S59 HPRD
O43521 (BCL2L11) S69 HPRD, neXtProt
O43521-1 (BCL2L11) S77 HPRD
O43602-2 (DCX) T321 Calculation
O43602-2 (DCX) T331 Calculation
O43602-2 (DCX) S334 Calculation
O60239-2 (SH3BP5) S194 HPRD
O60239-2 (SH3BP5) S264 HPRD
O60239 (SH3BP5) S351 HPRD, neXtProt
O60239-1 (SH3BP5) S421 HPRD
O95140 (MFN2) S27 Signor
P01106 (MYC) S62 Signor
P01106 (MYC) S71 Signor
P04150 (NR3C1) S226 neXtProt
P04637 (TP53) S6 Signor
P04637 (TP53) S20 Signor
P04637 (TP53) S37 neXtProt
P04637 (TP53) T81 Calculation
P05067-4 (APP) T668 Calculation
P05067 (APP) T743 neXtProt
P05412 (JUN) S63 Signor
P05412 (JUN) S73 Signor
P10636-8 (MAPT) T181 Calculation
P10636-8 (MAPT) S202 Calculation
P10636-8 (MAPT) T212 Calculation
P10636-8 (MAPT) T217 Calculation
P10636-8 (MAPT) T231 Calculation
P10636 (MAPT) T498 neXtProt
P10636 (MAPT) S516 neXtProt
P10636 (MAPT) S519 neXtProt
P10636 (MAPT) T529 neXtProt
P10636 (MAPT) T548 neXtProt
P10636 (MAPT) S713 neXtProt
P10636 (MAPT) S721 neXtProt
P10636 (MAPT) S739 neXtProt
P15036 (ETS2) T72 neXtProt
P15336 (ATF2) T69 Signor
P15336 (ATF2) T71 Signor
P15336 (ATF2) S90 Calculation
P16104 (H2AFX) S140 neXtProt, Signor
P16949 (STMN1) S25 neXtProt
P16949 (STMN1) S38 neXtProt, Signor
P19419-1 (ELK1) S383 HPRD
P19419 (ELK1) S389 HPRD, Signor
P19793 (RXRA) S56 neXtProt
P19793 (RXRA) S70 neXtProt
P19793 (RXRA) T82 neXtProt
P19793 (RXRA) S260 Signor
P23443 (RPS6KB1) S434 neXtProt
P29353 (SHC1) S36 neXtProt
P30307 (CDC25C) S168 Signor
P31645 (SLC6A4) T616 Calculation
P31947 (SFN) S186 Signor
P35222 (CTNNB1) S191 neXtProt, Signor
P35222 (CTNNB1) S605 neXtProt, Signor
P35568 (IRS1) S307 Signor
P35568 (IRS1) S315 Signor
P35568 (IRS1) Y612 Signor
P35568 (IRS1) Y632 Signor
P40763 (STAT3) S727 Signor
P41970 (ELK3) S357 HPRD, neXtProt
P41970 (ELK3) S363 neXtProt
P41970 (ELK3) S396 neXtProt
P41970 (ELK3) S401 neXtProt
P42224 (STAT1) S727 neXtProt
P46937 (YAP1) T119 neXtProt
P46937 (YAP1) S138 neXtProt
P46937 (YAP1) T154 neXtProt
P46937 (YAP1) S367 neXtProt
P49768 (PSEN1) S319 Signor
P49768 (PSEN1) T320 Signor
P50616 (TOB1) S152 Signor
P50616 (TOB1) S154 Signor
P50616 (TOB1) S164 Signor
P52945 (PDX1) S61 Calculation
P52945 (PDX1) S66 Calculation
P54259 (ATN1) S739 Signor
P55957 (BID) T59 Calculation
P63104 (YWHAZ) S184 Signor
P68431 (HIST1H3J) S29 neXtProt
P84243 (H3F3B) S29 HPRD, Signor
P98177 (FOXO4) T451 Calculation
P98177 (FOXO4) T455 Calculation
Q06481 (APLP2) T736 Calculation
Q07817 (BCL2L1) T47 Calculation
Q07817 (BCL2L1) S62 Calculation
Q07817 (BCL2L1) T115 Calculation
Q12968 (NFATC3) S163 Signor
Q12968-1 (NFATC3) S165 Signor
Q14653 (IRF3) S173 neXtProt
Q14934 (NFATC4) S213 Calculation
Q14934 (NFATC4) S217 Calculation
Q5JR12 (PPM1J) S93 Signor
Q8IW41 (MAPKAPK5) T182 Calculation
Q8WYK2 (JDP2) T148 Calculation
Q9BQQ3 (GORASP1) S274 Calculation
Q9NYV6 (RRN3) T200 Signor
Q9UIG0 (BAZ1B) S158 Signor
Q9UPT6 (MAPK8IP3) T265 neXtProt, Signor
Q9UPT6 (MAPK8IP3) T275 neXtProt, Signor
Q9UPT6 (MAPK8IP3) T286 neXtProt, Signor
Q9UQF2 (MAPK8IP1) T103 Signor
Substrate Site Source
O43521-2 (BCL2L11) S58 phospho.ELM
O43521-1 (BCL2L11) S59 HPRD
O43521-1 (BCL2L11) S69 HPRD, neXtProt
O43521-1 (BCL2L11) S77 HPRD
O43521 (BCL2L11) T116 Signor
O60282 (KIF5C) S176 neXtProt
O95644 (NFATC1) S172 Signor
P01106 (MYC) T58 Calculation
P01106 (MYC) S62 Calculation
P01106 (MYC) S71 Calculation
P04150 (NR3C1) S226 neXtProt
P04637 (TP53) S37 neXtProt
P05067-4 (APP) T668 Calculation
P05067 (APP) T743 neXtProt, Signor
P05412 (JUN) S63 neXtProt, Signor
P05412 (JUN) S73 Signor
P10415 (BCL2) T56 neXtProt
P10415 (BCL2) S70 neXtProt
P10415 (BCL2) T74 neXtProt
P10415 (BCL2) S87 neXtProt
P10636 (MAPT) T498 neXtProt
P10636 (MAPT) S516 neXtProt
P10636 (MAPT) S519 neXtProt
P10636 (MAPT) T522 neXtProt
P10636 (MAPT) T529 neXtProt
P10636 (MAPT) T534 neXtProt
P10636 (MAPT) S713 neXtProt
P10636 (MAPT) S721 neXtProt
P10636 (MAPT) S739 neXtProt
P16949 (STMN1) S25 neXtProt
P16949 (STMN1) S38 neXtProt, Signor
P29353 (SHC1) S36 neXtProt
P30307 (CDC25C) S168 Signor
P31947 (SFN) S186 Signor
P54259 (ATN1) S739 Signor
P55957 (BID) T59 Calculation
P61978-1 (HNRNPK) S216 HPRD, phospho.ELM, Signor
P61978-1 (HNRNPK) S284 HPRD
P61978-1 (HNRNPK) S353 HPRD, phospho.ELM, Signor
P63104 (YWHAZ) S184 Signor
Q06481 (APLP2) T736 Calculation
Q07820 (MCL1) S121 neXtProt
Q07820 (MCL1) T163 neXtProt
Q16600 (ZNF239) S38 neXtProt
Q16600 (ZNF239) S129 neXtProt
Q5JR12 (PPM1J) S93 Signor
Q93045 (STMN2) S62 neXtProt, Signor
Q93045 (STMN2) S73 neXtProt, Signor
Q9UPT6 (MAPK8IP3) T265 HPRD, neXtProt, Signor
Q9UPT6 (MAPK8IP3) T275 HPRD, neXtProt, Signor
Q9UPT6-1 (MAPK8IP3) T286 HPRD, neXtProt, Signor
IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v milk , 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking, overnight.